(EVK) Evonik Industries - Overview
Sector: Basic Materials | Industry: Specialty Chemicals | Exchange: XETRA (Germany) | Market Cap: 8.355m EUR | Total Return: -5.6% in 12m
Specialty Chemicals, Polymers, Additives, Animal Nutrition
Total Rating 40
Safety 66
Buy Signal 0.36
Specialty Chemicals
Industry Rotation: -7.9
Industry Rotation: -7.9
Market Cap:
9.79B
Avg Turnover: 21.6M
Avg Turnover: 21.6M
Risk 3d forecast
Volatility24.8%
VaR 5th Pctl4.27%
VaR vs Median4.34%
Reward TTM
Sharpe Ratio-0.29
Rel. Str. IBD59.7
Rel. Str. Peer Group65.2
Character TTM
Beta0.051
Beta Downside0.064
Hurst Exponent0.630
Drawdowns 3y
Max DD39.76%
CAGR/Max DD0.11
CAGR/Mean DD0.34
EPS (Earnings per Share)
EPS CAGR: -19.02%
EPS Trend: -19.5%
EPS Trend: -19.5%
Last SUE: 0.71
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: -8.45%
Rev. Trend: -87.7%
Rev. Trend: -87.7%
Last SUE: -2.07
Qual. Beats: -1
Qual. Beats: -1
Warnings
No concerns identified
Tailwinds
Confidence
Description: EVK Evonik Industries
Evonik Industries AG is a German specialty chemicals manufacturer headquartered in Essen, operating across five continents. The company organizes its production into three primary segments: Advanced Technologies, Custom Solutions, and Infrastructure. Its portfolio includes high-performance polymers, additives, crosslinkers, and essential amino acids for animal nutrition.
The business model focuses on high-margin specialty chemicals rather than high-volume commodities, allowing for greater integration into specialized supply chains like medical technology and automotive engineering. In the specialty chemicals sector, competitive advantage is often driven by proprietary formulations and the ability to meet stringent regulatory standards for pharmaceutical and food-grade applications.
For a deeper dive into these business segments and their historical performance, ValueRay provides comprehensive data tools.
Evonik serves diverse end-markets, providing hydrogen peroxide for electronics manufacturing, silicas for tire production, and plasticizers for the construction industry. Founded in 1847, the firm maintains a significant infrastructure division that supports the production of essential chemical precursors like butadiene and MTBE for the global rubber and fuel markets.
- Cyclical demand for animal nutrition methionine impacts specialty chemical segment margins
- Fluctuating energy and raw material costs in Germany pressure operational profitability
- Global automotive and tire production volumes drive demand for silica and silanes
- Strategic shift toward high-margin specialty chemicals reduces exposure to volatile commodities
- European environmental regulations and carbon pricing increase long-term manufacturing overhead costs
Piotroski VR‑10 (Strict)
5.5
| Net Income: 157.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -1.10 > 1.0 |
| NWC/Revenue: 13.35% < 20% (prev 14.49%; Δ -1.13% < -1%) |
| CFO/TA 0.08 > 3% & CFO 1.39b > Net Income 157.0m |
| Net Debt (2.69b) to EBITDA (1.52b): 1.76 < 3 |
| Current Ratio: 1.51 > 1.5 & < 3 |
| Outstanding Shares: last quarter (466.0m) vs 12m ago 0.0% < -2% |
| Gross Margin: 22.59% > 18% (prev 0.25%; Δ 2.23k% > 0.5%) |
| Asset Turnover: 70.91% > 50% (prev 74.79%; Δ -3.88% > 0%) |
| Interest Coverage Ratio: 1.48 > 6 (EBITDA TTM 1.52b / Interest Expense TTM 217.0m) |
Altman Z''
2.77
| A: 0.10 (Total Current Assets 5.43b - Total Current Liabilities 3.60b) / Total Assets 18.46b |
| B: 0.39 (Retained Earnings 7.21b / Total Assets 18.46b) |
| C: 0.02 (EBIT TTM 322.0m / Avg Total Assets 19.35b) |
| D: 0.70 (Book Value of Equity 7.06b / Total Liabilities 10.16b) |
| Altman-Z'' Score: 2.77 = A |
Beneish M
-3.01
| DSRI: 1.08 (Receivables 1.82b/1.87b, Revenue 13.72b/15.14b) |
| GMI: 1.09 (GM 22.59% / 24.74%) |
| AQI: 1.01 (AQ_t 0.33 / AQ_t-1 0.33) |
| SGI: 0.91 (Revenue 13.72b / 15.14b) |
| TATA: -0.07 (NI 157.0m - CFO 1.39b) / TA 18.46b) |
| Beneish M-Score: -3.01 (Cap -4..+1) = AA |
What is the price of EVK shares?
As of May 16, 2026, the stock is trading at EUR 17.81 with a total of 1,364,841 shares traded.
Over the past week, the price has changed by +3.01%, over one month by +6.33%, over three months by +14.76% and over the past year by -5.61%.
Over the past week, the price has changed by +3.01%, over one month by +6.33%, over three months by +14.76% and over the past year by -5.61%.
Is EVK a buy, sell or hold?
Evonik Industries has no consensus analysts rating.
What are the forecasts/targets for the EVK price?
| Analysts Target Price | - | - |
Evonik Industries (EVK) - Fundamental Data Overview
as of 13 May 2026
Market Cap USD = 9.79b (8.36b EUR * 1.1715 EUR.USD)P/E Trailing = 31.4561
P/E Forward = 19.9203
P/S = 0.609
P/B = 0.9935
P/EG = 6.2284
Revenue TTM = 13.72b EUR
EBIT TTM = 322.0m EUR
EBITDA TTM = 1.52b EUR
Long Term Debt = 2.59b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 684.0m EUR (from shortTermDebt, last quarter)
Debt = 3.28b EUR (corrected: LT Debt 2.59b + ST Debt 684.0m)
Net Debt = 2.69b EUR (recalculated: Debt 3.28b - CCE 589.0m)
Enterprise Value = 11.04b EUR (8.36b + Debt 3.28b - CCE 589.0m)
Interest Coverage Ratio = 1.48 (Ebit TTM 322.0m / Interest Expense TTM 217.0m)
EV/FCF = 18.07x (Enterprise Value 11.04b / FCF TTM 611.0m)
FCF Yield = 5.53% (FCF TTM 611.0m / Enterprise Value 11.04b)
FCF Margin = 4.45% (FCF TTM 611.0m / Revenue TTM 13.72b)
Net Margin = 1.14% (Net Income TTM 157.0m / Revenue TTM 13.72b)
Gross Margin = 22.59% ((Revenue TTM 13.72b - Cost of Revenue TTM 10.62b) / Revenue TTM)
Gross Margin QoQ = 25.21% (prev 20.25%)
Tobins Q-Ratio = 0.60 (Enterprise Value 11.04b / Total Assets 18.46b)
Interest Expense / Debt = 1.56% (Interest Expense 51.0m / Debt 3.28b)
Taxrate = 29.51% (54.0m / 183.0m)
NOPAT = 227.0m (EBIT 322.0m * (1 - 29.51%))
Current Ratio = 1.51 (Total Current Assets 5.43b / Total Current Liabilities 3.60b)
Debt / Equity = 0.40 (Debt 3.28b / totalStockholderEquity, last quarter 8.23b)
Debt / EBITDA = 1.76 (Net Debt 2.69b / EBITDA 1.52b)
Debt / FCF = 4.40 (Net Debt 2.69b / FCF TTM 611.0m)
Total Stockholder Equity = 8.30b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.81% (Net Income 157.0m / Total Assets 18.46b)
RoE = 1.89% (Net Income TTM 157.0m / Total Stockholder Equity 8.30b)
RoCE = 2.96% (EBIT 322.0m / Capital Employed (Equity 8.30b + L.T.Debt 2.59b))
RoIC = 2.31% (NOPAT 227.0m / Invested Capital 9.80b)
WACC = 4.73% (E(8.36b)/V(11.63b) * Re(6.16%) + D(3.28b)/V(11.63b) * Rd(1.56%) * (1-Tc(0.30)))
Discount Rate = 6.16% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF] Terminal Value 86.57% ; FCFF base≈723.8m ; Y1≈740.8m ; Y5≈823.2m
[DCF] Fair Price = 46.59 (EV 24.40b - Net Debt 2.69b = Equity 21.71b / Shares 466.0m; r=6.0% [WACC]; 5y FCF grow 2.21% → 3.0% )
EPS Correlation: -19.48 | EPS CAGR: -19.02% | SUE: 0.71 | # QB: 0
Revenue Correlation: -87.73 | Revenue CAGR: -8.45% | SUE: -2.07 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.42 | Chg30d=+28.79% | Revisions=+20% | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.41 | Chg30d=+2.50% | Revisions=+20% | Analysts=2
EPS current Year (2026-12-31): EPS=1.26 | Chg30d=+4.62% | Revisions=+56% | GrowthEPS=-7.1% | GrowthRev=+2.4%
EPS next Year (2027-12-31): EPS=1.40 | Chg30d=+1.79% | Revisions=+45% | GrowthEPS=+10.7% | GrowthRev=+0.9%
[Analyst] Revisions Ratio: +56%